Monday, November 6, 2017

Choroidal hemangioma in a patient with Stuge-Weber Syndrome

Sclera is at bottom of picture; retinal pigment epithelium is at top right. Between them is choroid with cavernous hemangioma

Wednesday, November 1, 2017

Guest Post from Sandro Santagata, MD, PhD: Papillary Craniopharyngioma Trial

I am pleased to present a guest post from Dr. Sandro Santagata of Brigham and Women’s Hospital/Dana Farber Cancer Center, who writes:



Our group of collaborators has recently opened a Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas that is sponsored by the Alliance for Clinical Trials in Oncology.

The eligibility criteria are listed here: https://clinicaltrials.gov/ct2/show/NCT03224767

The trial is based on work published in these two papers:


I am happy to answer any questions that our colleagues may have about this trial.  ssantagata@bics.bwh.harvard.edu

Tuesday, October 31, 2017

Neuropathology Blog is Ten Years Old Today


Ten years ago today, I put up the first post to neuropathology blog. At the time, I didn't intend for anyone to actually read any of this stuff. I thought the blog would be a convenient way of taking searchable notes on various neuropathology topics I came across.  Ten years (and 703 posts!) later, the blog has thus far had more than 850,000 page views. I'd like to particularly thank two early supporters: Drs. John Donahue and Mark Cohen. Thanks to both of you for your encouragement early on. And thanks to all the readers and contributors who have participated in making this blog a success over the last decade. Here's to ten more years!

Drs. John Donahue (left) and Mark Cohen

Friday, October 27, 2017

Neuropathologist Hannes Vogel featured in New York Times for examining brain of Las Vegas mass murderer

Prominent neuropathologist Hannes Vogel of Stanford University was featured in the New York Times yesterday as he is examining the brain of Stephen Paddock, who killed 58 concertgoers in Las Vegas this month in a rampage without any clear motive. Here's the link to the NYT article.


Hannes Vogel, MD

Wednesday, October 11, 2017

Audentes Therapeutics Announces Dosing of First Patient in ASPIRO, a Phase 1/2 Clinical Trial of AT132 for the Treatment of X-Linked Myotubular Myopathy

Following up on the last post, Dr. Mike Lawlor sent me this in an email:

"Audentes Therapeutics officially announced the dosing of the first patient for the X-linked myotubular myopathy treatment trial that we’ve been working on over the past few years.  We’ve been very involved in the translation from dogs to humans, and will be doing the human pathology work for the trial.  Here’s a link to that press release."

Monday, October 2, 2017

Lawlor featured in video about his work in myotubular myopathy

Michael Lawlor, MD, PhD

Medical College of Wisconsin is highlighting the work of our colleague Dr. Michael Lawlor in the area of gene therapy for myotubular myopathy. Check out this wonderful 4-minute video!

Thursday, September 28, 2017

Murat Gokden releases "Neuropathologic and Neuroradiologic Correlations: A Differential Diagnostic Text and Atlas"

I got this email from Johns Hopkins AP/NP Fellow Stephen Nix:

Murat Gokden, MD

"I'm not sure if this would be something to feature on the neuropathology blog or not, but Murat Gokden just edited and released a book with Cambridge Press entitled "Neuropathologic and Neuroradiologic Correlations" (link below) focusing on combining neuropathology and neuroradiology information/findings into one resource.  I just got my copy today and the images and text look great.  Pathology contributors include Travis Danielsen, Robin Elliott, Bret Evers, Theodore Friedman, Melissa Gener, Humayun Gultekin, Eyas Hattab, Ali Hussain, Mahlon D. Johnson, Nora Laver, Beatriz Lopes, Declan McGuone, Douglas C Miller, Robert Mrak, Veena Rajaram, Fausto Rodriguez, Amyn M Rojiani, Suash Sharma, Anat O. Stemmer-Rachamimov, and Mahtab Tehrani."



Here the link to what looks like a wonderful text:
https://www.cambridge.org/core/books/neuropathologic-and-neuroradiologic-correlations/1E16A2D262637648F8E3C54B443A3706#fndtn-information





Friday, September 22, 2017

Aaron Hernandez Had Severe C.T.E. When He Died at Age 27


The New York Times reported yesterday that an autopsy report on 27-year-old Aaron Hernandez, the former New England Patriots tight end and convicted murderer, showed evidence of severe chronic traumatic encephalopathy (CTE). Hernandez committed suicide earlier this year. 

Excerpts from the article:

"Dr. Ann McKee, chief of neuropathology at the VA Boston Healthcare System and director of the CTE Center at Boston University, examined his brain and said in a statement that Mr. Hernandez had “early brain atrophy” and “large perforations in the septum pellucidum, a central membrane” of the brain. The slides also showed what she called “classic features of C.T.E. in the brain,” including deposits of tau protein in the front lobes of the brain in nerve cells around small blood vessels."

"The trauma to Mr. Hernandez’s brain raises fresh questions about the dangers of playing tackle football. This week, other researchers at Boston University published research that found that adults who began playing tackle football before they were 12 years old developed more cognitive and behavioral problems later in life than those players who started tackle football after they reached that age."

Thanks to Dr. Mark Cohen for alerting me to this article.